University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Adam Boxer, M.D.

Neurologist

Dr. Adam Boxer is a neurologist at the UCSF Memory and Aging Center who specializes in Alzheimer's disease, frontotemporal dementia and atypical Parkinsonism (CBD and PSP). He obtained his medical and doctorate degrees as part of the NIH-funded Medical Scientist Training Program at New York University Medical Center. He completed a residency in neurology at Stanford University Medical Center and a fellowship in behavioral neurology at UCSF.

Boxer is an associate professor in UCSF's Department of Neurology. He directs the Neurosciences Clinical Research Unit at the Sandler Neurosciences Center at Mission Bay, as well as the Alzheimer's Disease and Frontotemporal Dementia Clinical Trials Program at the Memory and Aging Center. Boxer received the Edwin Boldrey Award from the San Francisco Neurological Society in 2002 for basic research in neurological disease, the 2005 John Douglas French Foundation Alzheimer's Award, and a 2009 Hellman Family Foundation fellowship.

Clinics

Memory and Aging Center
1500 Owens St., Suite 320
San Francisco, CA 94158
Phone: (415) 353-2057
Fax: (415) 476-4800

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about Adam Boxer

Education

New York University School of Medicine 1998

Residencies

Stanford Hospital and Clinics 2002

Selected Research and Publications

  1. Tsai RM, Boxer AL. Clinical trials: past, current, and future for atypical parkinsonian syndromes. Semin Neurol. 2014 Apr; 34(2):225-34.
  2. Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, Corvol JC, Ludolph A, Burn D, Lorenzl S, Litvan I, Roberson ED, Höglinger GU, Koestler M, Jack CR, Van Deerlin V, Randolph C, Lobach IV, Heuer HW, Gozes I, Parker L, Whitaker S, Hirman J, Stewart AJ, Gold M, Morimoto BH. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul; 13(7):676-85.
  3. Tartaglia MC, Hu B, Mehta K, Neuhaus J, Yaffe K, Miller BL, Boxer A. Demographic and Neuropsychiatric Factors Associated With Off-label Medication Use in Frontotemporal Dementia and Alzheimer's Disease. Alzheimer Dis Assoc Disord. 2014 Apr-Jun; 28(2):182-9.
  4. Pa J, Dutt S, Mirsky JB, Heuer HW, Keselman P, Kong E, Trujillo A, Gazzaley A, Kramer JH, Seeley WW, Miller BL, Boxer AL. The functional oculomotor network and saccadic cognitive control in healthy elders. Neuroimage. 2014 Jul 15; 95:61-8.
  5. Li Y, Chen JA, Sears RL, Gao F, Klein ED, Karydas A, Geschwind MD, Rosen HJ, Boxer AL, Guo W, Pellegrini M, Horvath S, Miller BL, Geschwind DH, Coppola G. An epigenetic signature in peripheral blood associated with the haplotype on 17q21.31, a risk factor for neurodegenerative tauopathy. PLoS Genet. 2014 Mar; 10(3):e1004211.
  6. Scherling CS, Hall T, Berisha F, Klepac K, Karydas A, Coppola G, Kramer JH, Rabinovici G, Ahlijanian M, Miller BL, Seeley W, Grinberg LT, Rosen H, Meredith J, Boxer AL. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol. 2014 Jan; 75(1):116-26.
  7. Sánchez-Juan P, Ghosh PM, Hagen J, Gesierich B, Henry M, Grinberg LT, O'Neil JP, Janabi M, Huang EJ, Trojanowski JQ, Vinters HV, Gorno-Tempini M, Seeley WW, Boxer AL, Rosen HJ, Kramer JH, Miller BL, Jagust WJ, Rabinovici GD. Practical utility of amyloid and FDG-PET in an academic dementia center. Neurology. 2014 Jan 21; 82(3):230-8.
  8. Kramer JH, Mungas D, Possin KL, Rankin KP, Boxer AL, Rosen HJ, Bostrom A, Sinha L, Berhel A, Widmeyer M. NIH EXAMINER: Conceptualization and Development of an Executive Function Battery. J Int Neuropsychol Soc. 2014 Jan; 20(1):11-9.
  9. Lee SE, Tartaglia MC, Yener G, Genç S, Seeley WW, Sanchez-Juan P, Moreno F, Mendez MF, Klein E, Rademakers R, Munain AL, Combarros O, Kramer JH, Kenet RO, Boxer AL, Geschwind MD, Gorno-Tempini ML, Karydas AM, Rabinovici GD, Coppola G, Geschwind DH, Miller BL. Neurodegenerative Disease Phenotypes in Carriers of MAPT p.A152T, A Risk Factor for Frontotemporal Dementia Spectrum Disorders and Alzheimer Disease. Alzheimer Dis Assoc Disord. 2013 Oct-Dec; 27(4):302-9.
  10. Fong H, Wang C, Knoferle J, Walker D, Balestra ME, Tong LM, Leung L, Ring KL, Seeley WW, Karydas A, Kshirsagar MA, Boxer AL, Kosik KS, Miller BL, Huang Y. Genetic correction of tauopathy phenotypes in neurons derived from human induced pluripotent stem cells. Stem Cell Reports. 2013; 1(3):226-34.
  11. Heuer HW, Mirsky JB, Kong EL, Dickerson BC, Miller BL, Kramer JH, Boxer AL. Antisaccade task reflects cortical involvement in mild cognitive impairment. Neurology. 2013 Oct 1; 81(14):1235-43.
  12. Almeida S, Gascon E, Tran H, Chou HJ, Gendron TF, Degroot S, Tapper AR, Sellier C, Charlet-Berguerand N, Karydas A, Seeley WW, Boxer AL, Petrucelli L, Miller BL, Gao FB. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol. 2013 Sep; 126(3):385-99.
  13. Possin KL, Feigenbaum D, Rankin KP, Smith GE, Boxer AL, Wood K, Hanna SM, Miller BL, Kramer JH. Dissociable executive functions in behavioral variant frontotemporal and Alzheimer dementias. Neurology. 2013 Jun 11; 80(24):2180-5.
  14. Miller ZA, Rankin KP, Graff-Radford NR, Takada LT, Sturm VE, Cleveland CM, Criswell LA, Jaeger PA, Stan T, Heggeli KA, Hsu SC, Karydas A, Khan BK, Grinberg LT, Gorno-Tempini ML, Boxer AL, Rosen HJ, Kramer JH, Coppola G, Geschwind DH, Rademakers R, Seeley WW, Wyss-Coray T, Miller BL. TDP-43 frontotemporal lobar degeneration and autoimmune disease. J Neurol Neurosurg Psychiatry. 2013 Sep; 84(9):956-62.
  15. Gardner RC, Boxer AL, Trujillo A, Mirsky JB, Guo CC, Gennatas ED, Heuer HW, Fine E, Zhou J, Kramer JH, Miller BL, Seeley WW. Intrinsic connectivity network disruption in progressive supranuclear palsy. Ann Neurol. 2013 May; 73(5):603-16.
  16. Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, Boxer AL, Dickson DW, Grossman M, Hallett M, Josephs KA, Kertesz A, Lee SE, Miller BL, Reich SG, Riley DE, Tolosa E, Tröster AI, Vidailhet M, Weiner WJ. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013 Jan 29; 80(5):496-503.
  17. Boxer AL, Knopman DS, Kaufer DI, Grossman M, Onyike C, Graf-Radford N, Mendez M, Kerwin D, Lerner A, Wu CK, Koestler M, Shapira J, Sullivan K, Klepac K, Lipowski K, Ullah J, Fields S, Kramer JH, Merrilees J, Neuhaus J, Mesulam MM, Miller BL. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013 Feb; 12(2):149-56.
  18. Kepe V, Bordelon Y, Boxer A, Huang SC, Liu J, Thiede FC, Mazziotta JC, Mendez MF, Donoghue N, Small GW, Barrio JR. PET imaging of neuropathology in tauopathies: progressive supranuclear palsy. J Alzheimers Dis. 2013 Jan 1; 36(1):145-53.
  19. Halabi C, Halabi A, Dean DL, Wang PN, Boxer AL, Trojanowski JQ, Dearmond SJ, Miller BL, Kramer JH, Seeley WW. Patterns of striatal degeneration in frontotemporal dementia. Alzheimer Dis Assoc Disord. 2013 Jan-Mar; 27(1):74-83.
  20. Sha SJ, Boxer A. Treatment implications of C9ORF72. Alzheimers Res Ther. 2012; 4(6):46.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.